[go: up one dir, main page]

WO1996035452A1 - Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires - Google Patents

Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires Download PDF

Info

Publication number
WO1996035452A1
WO1996035452A1 PCT/GB1996/001107 GB9601107W WO9635452A1 WO 1996035452 A1 WO1996035452 A1 WO 1996035452A1 GB 9601107 W GB9601107 W GB 9601107W WO 9635452 A1 WO9635452 A1 WO 9635452A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
acetylcysteine
expectorant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1996/001107
Other languages
English (en)
Inventor
Peter David Holtshousen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adcock Ingram Ltd
Original Assignee
Adcock Ingram Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcock Ingram Ltd filed Critical Adcock Ingram Ltd
Priority to AU56556/96A priority Critical patent/AU5655696A/en
Publication of WO1996035452A1 publication Critical patent/WO1996035452A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof

Definitions

  • This invention relates to a pharmaceutical composition.
  • South African Patent Application No. 94/0155 describes and claims a pharmaceutical composition in unit dosage form which comprises a therapeutic dose of acetylcysteine or carbocysteine and a therapeutic dose of terbutaline or pharmaceutically acceptable salt thereof.
  • the composition may be formulated as a capsule, tablet, synip, intravenous solution, nebulising solution, aerosol inhaler, dry powder inhaler or aqueous pump spray.
  • the composition is useful in the treatment of respiratory tract disorders.
  • South African Patents Nos. 92/1848 and 93/5931 describe simiiar pharmaceutical compositions, save that salbutamol or pharmaceutically acceptable salt thereof are used in place of terbutaline.
  • composition comprising as active ingredients:
  • the pharmaceutical composition of the invention will be provided in the form of dosage units with each unit containing each of the active ingredients.
  • the dosage units may be capsules, tablets, syrups, intravenous solutions, nebulising solutions, aerosol inhalers, dry powder inhalers, or aqueous pump sprays.
  • composition will provide each of the active ingredients in therapeutically effective amounts.
  • the acetylcysteine, carbocysteine, erdosteine or pharmaceutically acceptable salt thereof will be present in an amount sufficient to produce a mucolytic action;
  • the beta 2 agonist will be present in an amount sufficient to produce a bronchodilating action;
  • the expectorant will be present in an amount sufficient to produce an expectorant action.
  • the therapeutically effective amount of each active ingredient may be provided in a single dosage unit, e.g. a single tablet, teaspoon or intravenous unit, capsule, or may be provided in more than one dosage unit (multiple units), e.g. more than one tablet, capsule, teaspoon or intravenous unit.
  • the preferred beta 2 agonist is terbutaline, salbutamol or a pharmaceutically acceptable salt thereof.
  • the preferred expectorant is guaiphenesin.
  • Other useful expectorants are sodium citrate and ammonium chloride.
  • the pharmaceutical composition of the invention may be used in the treatment of respiratory tract disorders.
  • the composition has particular use in treating coughs, bronchitis, or chronic pulmonary conditions such as emphysema, chronic bronchitis and bronchicetasis.
  • the pharmaceutical composition will also contain one or more of the usual excipi ⁇ nts which are required to formulate the particular dosage unit.
  • a preferred composition of the invention contains, as active ingredients, acetylcysteine or a pharmaceutically acceptable salt thereof , terbutaline pharmaceutically acceptable salt thereof / and guaiphenesin.
  • a method of treatment of a human or animal patient suffering from a respiratory tract disorder comprising administering to said patient: (a) acetylcysteine, carbocysteine, erdosteine or a pharmaceutically acceptable salt of any of these; and (b) a beta 2 agonist; and (c) an expectorant.
  • the active ingredients are preferably each administered in a therapeutically effective amount.
  • Acetylcysteine 100-2000mg Terbutaline sulphate l-5mg Guaiphenesin 50-400mg Acid source 200-2500mg Alkali source 200-2500mg Flavours/colouring agents 5-200mg Diluent/binder 0-2000mg Lubricants 5-500mg
  • Aerosol inhaler (Dry powder inhaler or aqueous pump spray)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La composition pharmaceutique, qui est utile pour traiter les affections des voies respiratoires, contient comme principes actifs: (a) de l'acétylcystéine, de la carbocystéine, de l'erdostéine ou un sel acceptable sur le plan pharmaceutique d'un quelconque de ces composés; (b) un bêta 2 agoniste, p. ex. du salbutamol, de la terbutaline; et (c) un expectorant, p. ex. de la guaiphénésine, du citrate de sodium, du chlorure d'ammonium.
PCT/GB1996/001107 1995-05-10 1996-05-09 Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires Ceased WO1996035452A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56556/96A AU5655696A (en) 1995-05-10 1996-05-09 Pharmaceutical composition containing acetylcysteine, carboc ysteine or erdosteine in combination with a beta 2 agonist a nd an expectorant for the treatment of respiratory tract dis orders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA95/3778 1995-05-10
ZA953778 1995-05-10

Publications (1)

Publication Number Publication Date
WO1996035452A1 true WO1996035452A1 (fr) 1996-11-14

Family

ID=25585074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001107 Ceased WO1996035452A1 (fr) 1995-05-10 1996-05-09 Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires

Country Status (3)

Country Link
AU (1) AU5655696A (fr)
WO (1) WO1996035452A1 (fr)
ZA (1) ZA963590B (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059500A1 (fr) * 1999-04-06 2000-10-12 Zambon Group S.P.A. Comprimes a avaler a teneur elevee en n-acetylcysteine
WO2003068206A1 (fr) * 2002-02-13 2003-08-21 Adcock Ingram Intellectual Property (Proprietary) Limited Compositions pharmaceutiques comprenant terbutaline ou salbutamol associe a guaiphenesine
WO2005013963A1 (fr) 2003-08-06 2005-02-17 Galephar M/F Combinaisons avantageuses pour inhalation de nacystelyn et de bronchodilatateurs
CN1303065C (zh) * 2004-05-20 2007-03-07 江苏豪森药业股份有限公司 氨溴索半胱氨酸类似物盐及其制备方法和用途
EP1857106A1 (fr) * 2006-05-16 2007-11-21 Edmond Pharma S.R.L. Combinaisons de l'erdosteine et des agonistes beta-2 destinées au traitement de la bronchopneumopathie chronique obstructive (BPCO/COPD)
EP2068903A4 (fr) * 2006-10-03 2010-11-03 Galleon Pharmaceuticals Inc Composés de s-nitrosothiol, et dérivés associés
EP1940369A4 (fr) * 2005-09-20 2011-01-26 Galleon Pharmaceuticals Inc Combinaison de produits pharmaceutiques a base de s-nitrosothiol pour retablir un rythme respiratoire normal
WO2011030163A1 (fr) * 2009-09-12 2011-03-17 Reckitt Benckiser Llc Utilisation de guaifénésine pour inhiber la sécrétion de mucine
WO2011142677A1 (fr) * 2010-05-11 2011-11-17 Breathe Easy Ltd Méthodes et compositions pour le traitement de troubles pulmonaires
US20160120899A1 (en) * 2009-06-16 2016-05-05 Infirst Healthcare Limited Drug Combinations and Uses in Treating a Coughing Condition
US9675618B2 (en) 2009-06-16 2017-06-13 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9700561B2 (en) 2009-06-16 2017-07-11 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
WO2019212427A3 (fr) * 2017-12-30 2019-11-28 Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi Compositions comprenant de l'erdostéine et de l'acide ascorbique
CN113018444A (zh) * 2020-01-09 2021-06-25 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017746A1 (fr) * 1990-05-21 1991-11-28 Norwich Eaton Pharmaceuticals, Inc. Utilisation de phenylpropanolamine comme secretagogue muqueux des voies respiratoires superieures
ZA921848B (en) * 1991-05-10 1992-11-25 South African Druggists Ltd Pharmaceutical composition
EP0521388A1 (fr) * 1991-07-01 1993-01-07 Gerhard Dr. Gergely Procédé de préparation d'une composition pharmaceutique à base d'au mains deux principes actifs différents et utilisation d'une telle composition
ZA935931B (en) * 1992-08-18 1994-03-07 South African Druggists Ltd Pharmaceutical composition
ZA94155B (en) * 1992-11-06 1995-07-11 Adcock Ingram Pharma Pharmaceutical composition
DE19502566A1 (de) * 1994-01-31 1995-08-03 Zambon Int Pharma N-Acetyl-Cystein-haltige pharmazeutische Zusammensetzungen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017746A1 (fr) * 1990-05-21 1991-11-28 Norwich Eaton Pharmaceuticals, Inc. Utilisation de phenylpropanolamine comme secretagogue muqueux des voies respiratoires superieures
ZA921848B (en) * 1991-05-10 1992-11-25 South African Druggists Ltd Pharmaceutical composition
EP0521388A1 (fr) * 1991-07-01 1993-01-07 Gerhard Dr. Gergely Procédé de préparation d'une composition pharmaceutique à base d'au mains deux principes actifs différents et utilisation d'une telle composition
ZA935931B (en) * 1992-08-18 1994-03-07 South African Druggists Ltd Pharmaceutical composition
ZA94155B (en) * 1992-11-06 1995-07-11 Adcock Ingram Pharma Pharmaceutical composition
DE19502566A1 (de) * 1994-01-31 1995-08-03 Zambon Int Pharma N-Acetyl-Cystein-haltige pharmazeutische Zusammensetzungen

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. MINETTE: "Conclusions of an international symposium held at Aachen on 4 and 5 May about mucolytic agents, especially oral acetylcysteine", REV INST HYG MINES, vol. 34, no. 3, 1979, pages 159 - 165, XP002014822 *
C. MAAYAN ET AL.: "Immediate effect of various treatments on lung function in infants with cystic fibrosis", RESPIRATION, vol. 55, no. 3, 1989, pages 144 - 151, XP002014824 *
D. OLIVIERI: "Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis", RESPIRATION, vol. 58, no. 2, 1991, pages 91 - 94, XP002014823 *
DATABASE WPI Week 9315, Derwent World Patents Index; AN 93-126431, XP002014828 *
DATABASE WPI Week 9428, Derwent World Patents Index; AN 94-235044, XP002014827 *
DATABASE WPI Week 9548, Derwent World Patents Index; AN 95-374034, XP002014829 *
M. DEL DONNO ET AL.: "Efficacy of clenbuterol and ambroxol alone and in association on tracheal mucus velocity in chronic bronchitis", EUR RESPIR J, vol. 1, no. suppl. 2, 1988, pages 308s, XP002014825 *
W. COUET ET AL.: "Steady-state bioavailability and pharmacokinetics of ambroxol and clenbuterol administered alone and combined in a new oral formulation", INT J CLIN PHARMACOL THER TOXICOL, vol. 27, no. 9, 1989, pages 467 - 472, XP002014826 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059500A1 (fr) * 1999-04-06 2000-10-12 Zambon Group S.P.A. Comprimes a avaler a teneur elevee en n-acetylcysteine
WO2003068206A1 (fr) * 2002-02-13 2003-08-21 Adcock Ingram Intellectual Property (Proprietary) Limited Compositions pharmaceutiques comprenant terbutaline ou salbutamol associe a guaiphenesine
WO2005013963A1 (fr) 2003-08-06 2005-02-17 Galephar M/F Combinaisons avantageuses pour inhalation de nacystelyn et de bronchodilatateurs
CN1303065C (zh) * 2004-05-20 2007-03-07 江苏豪森药业股份有限公司 氨溴索半胱氨酸类似物盐及其制备方法和用途
EP1940369A4 (fr) * 2005-09-20 2011-01-26 Galleon Pharmaceuticals Inc Combinaison de produits pharmaceutiques a base de s-nitrosothiol pour retablir un rythme respiratoire normal
EP1857106A1 (fr) * 2006-05-16 2007-11-21 Edmond Pharma S.R.L. Combinaisons de l'erdosteine et des agonistes beta-2 destinées au traitement de la bronchopneumopathie chronique obstructive (BPCO/COPD)
WO2007131592A1 (fr) * 2006-05-16 2007-11-22 Edmond Pharma S.R.L. Combinaisons d'erdostéine et de bêta-2 agonistes pour traiter les bpco
EP2068903A4 (fr) * 2006-10-03 2010-11-03 Galleon Pharmaceuticals Inc Composés de s-nitrosothiol, et dérivés associés
US9675618B2 (en) 2009-06-16 2017-06-13 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US20160120899A1 (en) * 2009-06-16 2016-05-05 Infirst Healthcare Limited Drug Combinations and Uses in Treating a Coughing Condition
US9700561B2 (en) 2009-06-16 2017-07-11 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
AU2010294008B2 (en) * 2009-09-12 2014-08-14 Rb Health (Us) Llc Use of guaifenesin for inhibiting mucin secretion
WO2011030163A1 (fr) * 2009-09-12 2011-03-17 Reckitt Benckiser Llc Utilisation de guaifénésine pour inhiber la sécrétion de mucine
WO2011142677A1 (fr) * 2010-05-11 2011-11-17 Breathe Easy Ltd Méthodes et compositions pour le traitement de troubles pulmonaires
WO2019212427A3 (fr) * 2017-12-30 2019-11-28 Neutec Ar-Ge Sanayi Ve Ticaret Anonim Şirketi Compositions comprenant de l'erdostéine et de l'acide ascorbique
CN113018444A (zh) * 2020-01-09 2021-06-25 海南斯达制药有限公司 治疗呼吸系统疾病的药物组合物及其制备方法

Also Published As

Publication number Publication date
ZA963590B (en) 1996-11-19
AU5655696A (en) 1996-11-29

Similar Documents

Publication Publication Date Title
HK18695A (en) Inhalation medicaments for treating respiratory disorders
WO1996035452A1 (fr) Composition pharmaceutique contenant de l'acetylcysteine, de la carbocysteine ou de l'erdosteine en association avec un beta 2 agoniste et un expectorant pour le traitement des affections des voies respiratoires
CA2277365A1 (fr) Traitement de la sclerose en plaques par l'ingestion ou l'inhalation de copolymere-1
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
CA2334411A1 (fr) Utilisation d'une composition comprenant du formoterol et du budesonide pour la prevention ou le traitement d'un etat aigu d'asthme
CA2024872A1 (fr) Medicaments
EA022840B1 (ru) Фармацевтическая композиция, набор, их применение и способ профилактики и лечения симптома, состояния или заболевания, связанного с инфекцией вируса гриппа
JP2002528502A5 (fr)
WO1999040883A3 (fr) Compositions et techniques de traitement de la mucoviscidose
US5753712A (en) Treatment of migraine headaches and formulations
AU685741B2 (en) Sprayable analgesic composition and method of use
WO2004050025A3 (fr) Methode de traitement de la douleur aigue au moyen d'une forme posologique unitaire contenant de l'ibuprofene et de l'oxycodone
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物
CA2506962A1 (fr) Combinaison a base de roflumilast et de formoterol ayant un effet synergique
WO1995022324A1 (fr) Traitement des cephalees migraineuses et formulations
WO1995005816A1 (fr) Cromoglycate de sodium pour le traitement des infections des voies respiratoires superieures
JPH01228912A (ja) エアロゾル形態のペンタミジンを用いるニユーモシスチス・カリニ肺炎の予防方法
HUT64216A (en) Process for producing cough diminishing medical preparative containing dextrometorphane
CA2506956A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
MXPA03007017A (es) Medicamentos.
EP1249242B1 (fr) Composition phytothérapeutique à base des extraits hydroglycériques pour administration par aérosol
WO2003068206A1 (fr) Compositions pharmaceutiques comprenant terbutaline ou salbutamol associe a guaiphenesine
JP2000229853A (ja) 生理痛改善用組成物
CA2403674A1 (fr) Utilisation de triiodothyronine pour le traitement de l'insuffisance cardiaque congestive
JP2002370977A (ja) 局所適用組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA